P F Robbins
Overview
Explore the profile of P F Robbins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
2694
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Touloukian C, Leitner W, Robbins P, Rosenberg S, Restifo N
Cancer Res
. 2001 Nov;
61(22):8100-4.
PMID: 11719435
To identify novel, tumor-specific target antigens for vaccine development, we studied immune responses to P.polypeptide, an M(r) 110,000 integral melanosomal membrane protein associated with the Prader-Willi syndrome. Together with expressed...
2.
Lapointe R, Royal R, Reeves M, Altomare I, Robbins P, Hwu P
J Immunol
. 2001 Oct;
167(8):4758-64.
PMID: 11591807
Involvement of tumor-Ag specific CD4(+) and CD8(+) T cells could be critical in the generation of an effective immunotherapy for cancer. In an attempt to optimize the T cell response...
3.
Harada M, Li Y, Ohnmacht G, Rosenberg S, Robbins P
J Immunother
. 2001 Sep;
24(4):323-33.
PMID: 11565834
An autologous melanoma cell line selected for loss of expression of the immunodominant MART-1 and gp100 antigens was initially used to carry out a mixed lymphocyte tumor culture (MLTC) in...
4.
Housseau F, Moorthy A, Langer D, Robbins P, Gonzales M, Topalian S
Eur J Immunol
. 2001 Sep;
31(9):2690-701.
PMID: 11536167
Glycosylation of mammalian proteins is known to influence their intracellular trafficking, half life, and susceptibility to enzymatic degradation. Rare instances of natural T cell epitopes dependent upon glycosylation for recognition...
5.
Renkvist N, Castelli C, Robbins P, Parmiani G
Cancer Immunol Immunother
. 2001 Apr;
50(1):3-15.
PMID: 11315507
No abstract available.
6.
Zeng G, Wang X, Robbins P, Rosenberg S, Wang R
Proc Natl Acad Sci U S A
. 2001 Mar;
98(7):3964-9.
PMID: 11259659
NY-ESO-1 is a tumor-specific shared antigen with distinctive immunogenicity. Both CD8(+) T cells and class-switched Ab responses have been detected from patients with cancer. In this study, a CD4(+) T...
7.
Harada M, Li Y, Rosenberg S, Robbins P
Cancer Res
. 2001 Feb;
61(3):1089-94.
PMID: 11221837
An immunoselected melanoma cell line that had lost expression of the dominant melanoma antigens MART-1 and gp100 was generated in an attempt to identify previously unknown tumor antigens. After repeated...
8.
Touloukian C, Leitner W, Topalian S, Li Y, Robbins P, Rosenberg S, et al.
J Immunol
. 2000 Mar;
164(7):3535-42.
PMID: 10725708
CD4+ T cells play a central role in the induction and persistence of CD8+ T cells in several models of autoimmune and infectious disease. To improve the efficacy of a...
9.
Kawakami Y, Dang N, Wang X, Tupesis J, Robbins P, Wang R, et al.
J Immunother
. 2000 Feb;
23(1):17-27.
PMID: 10687134
A total of 123 tumor-infiltrating T lymphocyte (TIL) cultures established from patients with HLA-A1, -A2, -A3, -A24, or -A31 metastatic melanoma in the Surgery Branch, National Cancer Institute, were screened...
10.
Nishimura M, Avichezer D, Custer M, Lee C, Chen C, Parkhurst M, et al.
Cancer Res
. 2000 Jan;
59(24):6230-8.
PMID: 10626817
It is generally considered that MHC class I-restricted antigens are recognized by CD8+ T cells, whereas MHC class II-restricted antigens are recognized by CD4+ T cells. In the present study,...